Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Brincidofovir and Cyclosporine in Healthy Japanese Adults
NCT04542252Phase 1Completed
- Sponsor
- SymBio Pharmaceuticals
- Start
- Nov 2020
- Primary completion
- Dec 2020
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of brincidofovir in adenovirus infection and cytomegalovirus infection (CMV) (2 arms), sponsored by SymBio Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration of brincidofovir at 16 days and Area under the plasma concentration versus time curve of brincidofovir at 16 days. Started Nov 2020; status: completed.
02
Drugs
brincidofovir
03
Conditions
adenovirus infectioncytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT04542252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04542252.